Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of an acidic beverage on the absorption of erlotinib
2013-003603-19Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of erlotinib in bronchial carcinoma and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary pharmacokinetic endpoint. Started Feb 2014; status: active.
02
Drugs
erlotinib
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-003603-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003603-19.